The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research. The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy. Named for the infant son of preeclampsia survivor Lauren Pappas and her husband Clement, the program seeks to award multiple grants totaling up to $200,000 each year.
Investigators meeting the program’s criteria are invited to submit Letters of Intent for 2022 proposals by August 22, 2022. Letters of Intent that are of interest to the scientific review committee and the Preeclampsia Foundation’s Board of Directors will then be invited to submit full applications by October 8, 2022 with award decisions rendered in December 2022.
In addition to meeting the fund’s goals, preference will be given to proposals that use or build upon data available through the Preeclampsia Registry™ (self-reported, whole exome sequenced, and clinical data), or that will produce data or biological materials that can be added to the Registry’s data/bio repository. In addition to utilizing the Registry and its rich assets, proposals must align with the Preeclampsia Foundation’s vision of a world where preeclampsia no longer threatens the lives of mothers and their babies. Examples of such proposals include but are not limited to understanding pathophysiological pathways and subtypes of preeclampsia, mechanisms for improved diagnosis or prediction, and therapeutic interventions to halt, reverse, or prevent the placental and organ dysfunction associated with the condition.
“We lost our son Peter due to preeclampsia following a 29-week delivery,” explained Lauren Pappas. “Since then we have dedicated our lives to helping others avoid the same outcome by establishing the Peter Joseph Pappas Fund.”
“Thanks to generous contributions from family and friends, and our partnership with the Preeclampsia Foundation, we are making strides to reach our ultimate goal of eliminating pre-term births due to preeclampsia by 2050,” added Clement Pappas.
The Peter Joseph Pappas Research Grants program adds to the Preeclampsia Foundation’s portfolio of research programs including the Vision Grant program for young investigators, PRIME for health services research, EMPOWER, which helps build research capacity in low- and middle-income countries, and the Preeclampsia Registry, a dynamic database of research participants including preeclampsia and HELLP syndrome survivors, family members, and controls (unaffected individuals).
Complete details can be found online at www.preeclampsia.org/research-funding. Letters of intent are due by Monday, August 22, 2022 via email to PJPGrants@preeclampsia.org.
About the Preeclampsia Foundation
The Preeclampsia Foundation is a U.S.-based 501(c)(3) not-for-profit organization established in 2000. Its purpose is to improve the outcomes of hypertensive disorders of pregnancy by educating, supporting and engaging the community, improving healthcare practices, and finding a cure. The Preeclampsia Foundation envisions a world where hypertensive disorders of pregnancy no longer threaten the lives of mothers and their babies. For more information, visit www.preeclampsia.org.
About the Peter Joseph Pappas Fund
Clement and Lauren Pappas of Philadelphia, PA, lost their firstborn child, Peter Joseph, after HELLP syndrome necessitated his early delivery. Their son, born at 29 weeks’ gestation, spent a week in the neonatal intensive care unit before dying from a central line infection. The Pappas family, along with friends and family, have established a special fund with the Preeclampsia Foundation to advance research, with the overarching goal of eliminating pre-term births due to preeclampsia by 2050.
About The Preeclampsia Registry
The first of its kind to focus solely on hypertensive disorders of pregnancy, The Preeclampsia Registry captures self-reported and clinical information (medical records) as well as family and pregnancy history, and DNA. Overseen by an Institutional Review Board, the Registry ensures participants’ privacy and rights in medical research. The Registry only shares de-identified information with approved scientists, researchers, and clinicians. Launched in 2013, it currently includes over 7,000 participants from every state in the nation as well as dozens of countries around the world.
Our mission is to find a cure for preeclampsia and other related hypertensive disorders of pregnancy. Join us and apply for funding to help us save moms and their babies.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
May 19, 2023 – NEW YORK – Thermo Fisher Scientific announced on Friday, May 19 that it has obtained clearance from the US Food and Drug Administration for two assays to assess risk of...
A new research study published out of the UK in April 2023 in Hypertension found that more than half of all preeclampsia cases which occur during weeks 37-42 of pregnancy (“at-term”) may b...
Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero If given in early pregnancy pravastatin, (a drug used to lower cholesterol) may decrease the risk of developing pree...
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy (a rat model) Currently the only treatment for preeclampsia starts with delivery of the baby and the placenta....
The nuMom2b study – short for “Nulliparous* Pregnancy Outcomes Study: Monitoring Mothers-To-Be” – is a prospective study that enrolled over 10,000 first time pregnant women acr...